Last updated on March 2018

A clinical trial sponsored by Merck Sharp & Dohme Corp. for a research study for the treatment of Bacterial pneumonia

Brief description of study

This study aims to compare treatment with imipenem/relebactam/cilastatin (IMI/REL) as a fixed-dose combination (FDC) with piperacillin/tazobactam (PIP/TAZ) FDC in participants with hospital-acquired and ventilator-associated bacterial pneumonia. The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ in the incidence rate of all-cause mortality.

Clinical Study Identifier: NCT02493764

Contact Investigators or Research Sites near you

Start Over

Eran Gefen

Merck Sharp & Dohme Bulgaria EOOD
Sofia, Bulgaria
  Connect »